BIRC5 and cutaneous melanoma: Except for prostate adenocarcinoma, sarcoma, cutaneous melanoma, thyroid carcinoma, and thymoma, BIRC5 was significantly elevated (p < 0.05) in all nineteen cancers based on the pan-cancer analysis results (Table 2).